Alzheimer's Disease/Cognition News

C2N Diagnostics released the PrecivityAD2 blood test, which uses positron emission tomography scans and cerebrospinal fluid tests to assist in accurate diagnosis for those presenting with signs or symptoms of Alzheimer’s disease.

A Bay Area clinical research and development firm announced it will discontinue development of a novel therapeutic for Alzheimer’s disease.

Treatment with an investigational anti-amyloid therapeutic for adults with mild Alzheimer’s disease was safe, efficacious and demonstrated a significant immune response up to 78 weeks, per a study published in EBioMedicine.

A neuroscience company and an emerging artificial intelligence technology firm have announced a partnership that aims to boost access to routine brain care and to facilitate early detection of Alzheimer’s disease and related dementias.

Adults older than 60 years have significantly worse cognition and higher depression after experiencing moderate to severe trauma, according to research presented at the Alzheimer’s Association International Conference.

At the recent Alzheimer's Association International Conference in Amsterdam, an Alzheimer’s Association workgroup proposed revisions to the diagnostic criteria for Alzheimer’s disease.

Early menopause and vascular processes may synergistically contribute to increased risk for Alzheimer’s disease in women, according to a poster presentation at the Alzheimer’s Association International Conference.

Quest Diagnostics has announced the availability of a blood-based test that assesses the risk of developing Alzheimer’s disease through amyloid-beta biomarkers.

NYU Langone Hospitals was named the top hospital in the United States for neurology and neurosurgery by the U.S. News & World Report’s annual Best Hospitals survey.

New guidance from the American Academy of Neurology on early Alzheimer’s disease treatment calls for greater collaboration from patients, caregivers and clinicians as well as the embrace of new therapeutics.